Filing Details

Accession Number:
0001415889-13-000016
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-01-03 19:19:54
Reporting Period:
2012-12-28
Filing Date:
2013-01-03
Accepted Time:
2013-01-03 19:19:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1374328 Bond Laboratories Inc. BNLB.OB Medicinal Chemicals & Botanical Products (2833) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1497703 S John Wilson 4509 S. 143Rd Street
Suite 1
Omaha NE 68137
Chief Executive Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-12-28 1,050,564 $0.00 3,699,570 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option $0.10 2011-06-08 2021-06-08 500,000 500,000 Direct
Common Stock Warrant $0.15 2008-12-31 2013-12-31 1,000,000 1,000,000 Direct
Common Stock Stock Option $0.09 2012-04-13 2017-04-13 500,000 500,000 Direct
Common Stock Series C Convertible Preferred Stock $0.25 668,000 17 Direct
Common Stock Warrant $0.30 2015-11-15 332,500 332,500 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2021-06-08 500,000 500,000 Direct
2013-12-31 1,000,000 1,000,000 Direct
2017-04-13 500,000 500,000 Direct
668,000 17 Direct
2015-11-15 332,500 332,500 Direct
Footnotes
  1. The Reporting Person acquired the shares of the Issuer's common stock ("Common Stock") for aggregate consideration of $12,500 in a privately negotiated transaction.
  2. The Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock ("Series C Preferred") contains a provision preventing the conversion of the Series C Preferred if, as a result of such conversion, the Reporting Person would beneficially own, together with all other shares of Common Stock beneficially owned by the Reporting Person, in excess of 4.99% of the Issuer's Common Stock issued and outstanding.
  3. The Series C Preferred are perpetual.
  4. Each share of Series C Preferred is convertible into that number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing $10,000 per share (the liquidation preference) by the conversion price then in effect, or $0.25 on the date of this Report. Conversion of the Series C Preferred is subject to the limitation on conversion described in Note 2.
  5. The Warrant contains a provision preventing the exercise of the Warrant if, as a result of such exercise, the Reporting Person would beneficially own, together with all other shares of Common Stock beneficially owned by the Reporting Person, in excess of 9.99% of the Issuer's Common Stock issued and outstanding.